Somatropin
Published research and evidence base
Somatropin is a 191-amino-acid recombinant form of human growth hormone that acts through the growth hormone receptor and the downstream JAK/STAT pathway, largely via hepatic and local induction of insulin-like growth factor 1 (IGF-1). It has been an approved therapeutic since the mid-1980s and carries one of the larger clinical evidence bases in endocrinology, spanning childhood and adult growth hormone deficiency, Turner syndrome, Prader-Willi syndrome, small-for-gestational-age short stature and idiopathic short stature. The contemporary literature is dominated by systematic reviews, network meta-analyses and consensus statements, with a recent centre of gravity on long-acting weekly analogues (somapacitan, somatrogon, lonapegsomatropin, pegylated formulations) benchmarked against daily somatropin. Long-term registry and cohort surveillance has focused on mortality, malignancy incidence and metabolic outcomes.
- Studies cited
- 16
- Published 2023+
- 13
- Newest paper
- 2026
- Last reviewed
- Aug 2026
Recurring themes in the literature
- growth hormone deficiency
- IGF-1
- GH/IGF-1 axis
- long-acting growth hormone analogues
- height velocity and adult height
- Turner syndrome
- Prader-Willi syndrome
- small for gestational age
- transition care
- body composition
- treatment adherence
- long-term safety surveillance
16 published studies.
Ordered by strength of study design, then by recency. Every entry links to its source record so the finding can be checked against the paper rather than taken on our word.
- 01Clinical guideline2025
Long-Acting Growth Hormone Therapy in Pediatric Growth Hormone Deficiency: A Consensus Statement
Maniatis A, et al. · The Journal of Clinical Endocrinology and Metabolism · international consensus statement, panel of 11 paediatric endocrinology experts from 10 countries
The panel recorded that weekly long-acting formulations reduce injection frequency and treatment burden relative to daily somatropin and may support adherence, while noting that long-term and real-world outcome data remain lacking.
- 02Clinical guideline2025
Consensus and controversies about diagnosing GH deficiency: a Delphi survey by the GH research society
Arlien-Søborg MC, et al. · Pituitary · Delphi survey, 43 panellists (18 paediatric, 25 adult endocrinologists) from 14 countries
Agreement on diagnostic criteria for growth hormone deficiency was substantially higher among adult endocrinologists (88%) than paediatric endocrinologists (59%), with the principal areas of disagreement concerning the choice and interpretation of stimulation tests.
- 03Clinical guideline2023
International Consensus Guideline on Small for Gestational Age: Etiology and Management From Infancy to Early Adulthood
Hokken-Koelega ACS, et al. · Endocrine Reviews · international consensus guideline informed by systematic review of approximately 1,300 articles, experts from 10 paediatric endocrine societies
The guideline set out management of short stature persisting after birth small for gestational age, including timing of growth hormone initiation in early childhood and the option of adjunctive GnRH analogue therapy in selected cases to optimise adult height.
- 04Clinical guideline2022
Safety of growth hormone replacement in survivors of cancer and intracranial and pituitary tumours: a consensus statement
Boguszewski MCS, et al. · European Journal of Endocrinology · international consensus statement, 55 participants representing 10 professional societies
The panel concluded that the evidence reviewed did not support an association between growth hormone replacement and primary tumour recurrence or cancer recurrence in survivors, while recommending continued surveillance.
- 05Systematic review2026
Long-Acting Growth Hormone Versus Daily Growth Hormone for Growth Hormone Deficiency Patients: A Network Meta-Analysis of Clinical Trials
Abadi A, et al. · Endocrinology, Diabetes & Metabolism · network meta-analysis of 18 randomised controlled trials, n=3,137 patients with growth hormone deficiency
Once-weekly long-acting formulations were broadly comparable to daily somatropin for linear growth outcomes, with weekly PEGylated rhGH ranking highest for height velocity in the network and no signal of compromised safety across comparators.
- 06Systematic review2026
Comparison of efficacy and safety between long-acting growth hormone and short-acting growth hormone in isolated growth hormone deficiency: a systematic review and meta-analysis of 16 randomized controlled trials involving 2,435 pediatric patients
Shen ZZ, et al. · Frontiers in Pediatrics · systematic review and meta-analysis of 16 randomised controlled trials, n=2,435 paediatric patients with isolated growth hormone deficiency
Long-acting preparations showed a small advantage in first-year height gain over daily somatropin, the effect being concentrated in the PEGylated subgroup, while adverse event rates were comparable between the two treatment schedules.
- 07Systematic review2026
Long-acting growth hormone for treating growth hormone deficiency in children: a meta-analysis of randomized controlled trials focusing on changes in body mass index
Levaillant L, et al. · The Journal of Clinical Endocrinology and Metabolism · meta-analysis of randomised controlled trials with extension phases, n=585 children (346 long-acting, 239 daily)
BMI standard deviation score rose significantly over the first 12 months in children receiving long-acting growth hormone, whereas no comparable change was observed with daily somatropin, identifying a metabolic difference between the two dosing schedules.
- 08Systematic review2026
Safety and efficacy of somapacitan in adults with growth hormone deficiency who were switched from daily growth hormone therapy: A systematic review and meta-analysis
Kamrul-Hasan ABM, et al. · Growth Hormone & IGF Research · systematic review of 5 studies with meta-analysis of 4 randomised controlled trials, n=297 adults switched from daily rhGH
Switching adults from daily somatropin to once-weekly somapacitan maintained comparable efficacy and safety, with modest differences reported in glucose homeostasis measures and no excess of serious adverse events.
- 09Systematic review2026
GH-IGF-1 axis and rhGH outcomes in children with GHD, ISS and SGA: a systematic review and meta-analysis
Soliman AT, et al. · Journal of Pediatric Endocrinology & Metabolism · systematic review and meta-analysis of 47 studies (2005-2024), n=18,642 children (9,214 GHD, 6,807 ISS, 2,621 SGA)
First-year height velocity response to rhGH was greatest in complete growth hormone deficiency, exceeding idiopathic short stature by approximately 0.80 cm/year and small-for-gestational-age short stature by approximately 0.62 cm/year, indicating diagnosis-dependent responsiveness of the GH/IGF-1 axis.
- 10Systematic review2025
Long-term growth hormone effects in Prader-Willi syndrome: A systematic review and meta-analysis
Almutadares MN, et al. · Saudi Medical Journal · systematic review of 41 studies with 30 pooled in meta-analysis, patients with Prader-Willi syndrome
Growth hormone treatment was associated with increases in height standard deviation score of approximately 1.05 to 1.53 depending on treatment duration, reductions in BMI standard deviation score and elevated IGF-1, with the authors emphasising the need for metabolic monitoring.
- 11Systematic review2024
Efficacy and Safety of Somapacitan Relative to Somatrogon and Lonapegsomatropin in Pediatric Growth Hormone Deficiency: Systematic Literature Review and Network Meta-analysis
de Fries Jensen L, et al. · Advances in Therapy · systematic literature review with Bayesian network meta-analysis, 6 trials (2 somapacitan, 3 somatrogon, 1 lonapegsomatropin)
No statistically significant differences in 52-week growth outcomes were detected between somapacitan, somatrogon and lonapegsomatropin, and all three were comparable to daily somatropin in efficacy and tolerability.
- 12Systematic review2024
Growth Hormone Treatment to Final Height in Turner Syndrome: Systematic Review
Aversa T, et al. · Clinical Therapeutics · systematic review of 9 studies published 2010-2021 in Turner syndrome
Growth hormone treatment at adequate dose was associated with attainment of adult heights within the target range, with the largest height gains accrued during the prepubertal period; karyotype did not predict treatment response.
- 13Systematic review2023
Meta-analysis of mortality in adults with growth hormone deficiency: Does growth hormone replacement therapy really improve mortality rates?
van Bunderen CC, Olsson DS · Best Practice & Research. Clinical Endocrinology & Metabolism · meta-analysis of observational cohort studies of adults with growth hormone deficiency
Although mortality in hypopituitary cohorts appeared closer to background rates in the growth hormone replacement era, the authors concluded that selection bias and time bias precluded high-quality evidence that replacement itself improves mortality.
- 14Human clinical2026
Accumulated safety data of recombinant human growth hormone therapy in Korean children over a 10-year period: interim results from the LG Growth Study
Kim YM, et al. · Endocrine Connections · prospective multicentre observational registry, n=5,040 children, 19,878 patient-years (2011-2022)
Adverse drug reactions were reported in 7.0% of registry participants and serious adverse drug reactions in 0.3%, with a malignancy standardised incidence ratio of 1.1 relative to national expectation.
- 15Human clinical1989
The effects of treatment with recombinant human growth hormone on body composition and metabolism in adults with growth hormone deficiency
Salomon F, et al. · The New England Journal of Medicine · double-blind placebo-controlled trial, n=24 adults with growth hormone deficiency, 6 months
Recombinant human growth hormone replacement increased lean body mass by approximately 5.5 kg and decreased fat mass by approximately 5.7 kg over six months, establishing adult growth hormone deficiency as a treatable body-composition phenotype.
- 16Review2018
Growth hormone - past, present and future
Ranke MB, Wit JM · Nature Reviews Endocrinology · narrative review covering the history, physiology and therapeutic development of growth hormone
The review traced the transition from cadaveric pituitary-derived growth hormone to recombinant 191-amino-acid somatropin, the expansion of approved indications beyond classical deficiency, and the recurring safety questions attached to that expansion.
What this evidence does not establish.
Head-to-head long-term data comparing weekly long-acting analogues with daily somatropin remain short in duration, so adult height, sustained metabolic effects and real-world adherence outcomes are not yet established, and the BMI increase observed with long-acting formulations in the first treatment year is of uncertain durability and clinical meaning. Diagnostic criteria for growth hormone deficiency, particularly stimulation-test thresholds in children and at the paediatric-to-adult transition, remain contested, and observational mortality and malignancy surveillance is constrained by selection bias and limited follow-up duration.
Common questions about the research.
- What is Somatropin?
Somatropin is recombinant human growth hormone — a 191-amino-acid polypeptide identical in sequence to the hormone produced by the anterior pituitary, manufactured in engineered host cells. It acts directly at the growth hormone receptor.
- How does it differ from Ipamorelin or CJC-1295?
Somatropin is the hormone itself. Ipamorelin and CJC-1295 are secretagogues that prompt the pituitary to release its own growth hormone, which means their effect depends on pituitary reserve and remains subject to endogenous feedback. Somatropin bypasses that step entirely.
- What does long-term safety surveillance of somatropin show?
A prospective multicentre observational registry covering 5,040 children and 19,878 patient-years between 2011 and 2022 recorded adverse drug reactions in 7.0 percent of participants and serious adverse drug reactions in 0.3 percent, with a malignancy standardised incidence ratio of 1.1 relative to national expectation. A 2022 international consensus statement representing ten professional societies concluded that the evidence reviewed did not support an association between growth hormone replacement and primary tumour recurrence or cancer recurrence in survivors, while recommending continued surveillance. Observational mortality and malignancy surveillance remains constrained by selection bias and limited follow-up duration.
Available from our catalog
For research purposes only. Not for human consumption, diagnosis, treatment, or prevention of any condition. Nothing on this page is medical advice, and no study summarised here should be read as a recommendation.